METASTATIC GASTRIC AND OESOPHAGO-GASTRIC CANCERS

ROOM 324
SUNTEC, SINGAPORE

Chairs:
Florian Lordick, Germany
Kei Muro, Japan

SUNDAY, 25 NOVEMBER 2018
09:15 - 10:15

09:15 Introduction
Kei Muro, Nagoya, Japan

09:20 1st line treatment options for patients without a biomarker driven option
Li-Tzong Chen, Tainan, Taiwan

09:30 Biomarker driven option in 1st line treatment options
Chau Matthew Ng, Singapore

09:40 2nd and later lines of treatment: What are the options?
Florian Lordick, Leipzig, Germany

09:50 Is there some hope from immunotherapy in metastatic gastric cancer?
Yung-Jue Bang, Seoul, Republic of Korea

10:00 What’s new in the Guidelines?
Kei Muro, Nagoya, Japan

10:10 Conclusions
Florian Lordick, Leipzig, Germany

This educational activity is provided by ESMO and supported by Lilly.